×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Progressive Supranuclear Palsy (PSP) Treatment
therapeutic
2,746 words
KG: ent-dise-bfd8f32d
2026-03-22
kind:therapeutic
section:therapeutics
state:published
Contents
Progressive Supranuclear Palsy (PSP) Treatment
💊
Therapeutic Info
Name
Progressive Supranuclear Palsy (PSP) Treatment
Summary
Treatment approaches for Progressive Supranuclear Palsy including symptomatic management and emerging disease-modifying therapies
Knowledge Graph
Related Hypotheses (14)
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Aquaporin-4 Polarization Rescue
Score: 0.51
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
APOE-Dependent Autophagy Restoration
Score: 0.61
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
APOE-TREM2 Interaction Modulation
Score: 0.48
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
Show 9 more
Related Analyses (8)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Show 3 more
Related Experiments (30)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.90
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.40
NPH Glymphatic System Interaction Experiment
clinical · proposed · Score: 0.40
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.40
Show 25 more